Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
/ 1659 items
#XY↓
Goldman Sachs Highlights Corvus Pharmaceuticals as a Promising Oral Player in $24 Billion Atopic Dermatitis Market
Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.
AxoGen Stock Jumps as Cigna Adds Coverage for Avance Nerve Graft in Breast Reconstruction
AxoGen shares rose after Cigna will cover its nerve graft from Apr 2026, helping more patients get nerve repair after surgery.
MeiraGTx Stock Drops After $100M Share Offering and Bota-Vec Buy from Johnson & Johnson
MeiraGTx stock fell after $100M share sale to raise cash. Money will fund gene therapy drugs and future launches.
Achieve Life Sciences Stock Jumps as New CEO and $354 Million Funding Fuel Launch of First New Quit-Smoking Pill in 20 Years
Achieve Life Sciences jumps after CEO change, funding news, and progress on smoking/vaping quit drug cytisinicline.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.